Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

References

• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486–500.
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168–74.
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–86.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298–305.
   PubMed Web of Science ®Google Scholar
• Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49:S103–11.
   PubMed Web of Science ®Google Scholar
• Sjogren MH. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004;19(Suppl 6):S69–72.
   Google Scholar
• Janssen HLA, Van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet 2005;365:123–9.
   PubMed Web of Science ®Google Scholar
• Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E, A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody–and hepatitis B virus DNA–positive chronic hepatitis B. Hepatology 1996;24:774–7.
   PubMed Web of Science ®Google Scholar
• Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27:1383–7.
   PubMed Web of Science ®Google Scholar
• Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M, The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat 2005;12:300–6.
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol 2006;12:6715–21.
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol 2001;7:411–14.
   PubMedGoogle Scholar
• Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S, A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000;45:690–6.
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77:136–41.
   PubMed Web of Science ®Google Scholar
• Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci 2003;92:1386–95.
   PubMed Web of Science ®Google Scholar
• Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999;6:397–403.
   PubMed Web of Science ®Google Scholar
• De Roy PG. Helsinki and the Declaration of Helsinki. World Med J 2004;50:9–11.
   Google Scholar
• Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191–4.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682–95.
   PubMed Web of Science ®Google Scholar
• Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34:483–6.
   PubMed Web of Science ®Google Scholar
• Chow S, Shao J, Wang H. Sample size calculations in clinical research 2003; Marcel Dekker Inc.; New York: NY, US.
   Google Scholar
• Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001;7:407–10.
   PubMed Web of Science ®Google Scholar
• Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005;48:133–7.
   PubMed Web of Science ®Google Scholar
• Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J Viral Hepat 2006;13:845–50.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2009;136:505–12.
   PubMed Web of Science ®Google Scholar
• European Association For the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151–7.
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141–50.
   PubMed Web of Science ®Google Scholar
• Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428–34.
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008;6:1022–6.
   PubMedGoogle Scholar
• Lok AS-F. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;132:1586–94.
   PubMed Web of Science ®Google Scholar